Amylin Pharmaceuticals to Present at Thomas Weisel Healthcare, BioCentury NewsMakers, and Morgan Stanley Global Healthcare Conferences

Friday, August 29, 2008 General News J E 4
SAN DIEGO, Aug. 28 Amylin Pharmaceuticals, Inc.(Nasdaq: AMLN) will be presenting at the Thomas Weisel Healthcare Conferencein Boston on Wednesday, September 3, 2008 at 9:10 a.m. ET, at the BioCenturyNewsMakers Conference in New York on Thursday, September 4, 2008 at 11:30 a.m.ET, and at the Morgan Stanley Global Healthcare Unplugged Conference in NewYork on Tuesday, September 9, 2008 at 10:55 a.m. ET. Mark G. Foletta, Amylin'sSenior Vice President of Finance and Chief Financial Officer, will beproviding corporate overviews at Thomas Weisel and BioCentury. Daniel M.Bradbury, Amylin's President and Chief Executive Officer, will be providing acorporate overview at Morgan Stanley.

The live presentations will be Web cast, and recordings will be madeavailable following the event. The Web casts and recordings will be accessiblethrough Amylin's corporate Web site, located at Toaccess the live Web casts, please log on to Amylin's site approximatelyfifteen minutes prior to the presentations to register and download anynecessary audio software.

About Amylin Pharmaceuticals

Amylin Pharmaceuticals is a biopharmaceutical company committed toimproving lives through the discovery, development and commercialization ofinnovative medicines. Amylin has developed and gained approval for twofirst-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate)injection and BYETTA(R) (exenatide) injection. Amylin's research anddevelopment activities leverage the company's expertise in metabolism todevelop potential therapies to treat diabetes and obesity. Amylin isheadquartered in San Diego, California with over 2,000 employees nationwide.Further information on Amylin Pharmaceuticals is available at

SOURCE Amylin Pharmaceuticals, Inc.


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Orexigen(R) Therapeutics to Present at Upcoming In...
CRH Medical reports Q2 2008 results